CLEERLY TAKES PRECISION HEART CARE TO THE NEXT LEVEL WITH CLEERLY 2.2.0Cleerly 2.2.0 includes UX updates and three high-value tools to better evaluate heart disease NEW YORK, February 8, 2022 — Cleerly, the company creating a new standard of care for heart...
Sierra Oncology Announces Momelotinib Achieved Statistically Significant Benefit on Symptoms, Anemia and Splenic Size in the Pivotal MOMENTUM Study for Myelofibrosis —New Drug Application submission planned for second quarter of 2022— —Full data set to be presented at...
Sierra Oncology Announces Pricing of Upsized Public Offering of Securities SAN MATEO, Calif.–(BUSINESS WIRE)– Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, today...
Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTAC® Protein Degrader ARV-471 – Collaboration combines Arvinas’ investigational estrogen receptor-targeting breast cancer therapy with Pfizer’s deep experience in breast oncology...
ADDEX THERAPEUTICS INITIATES PIVOTAL PHASE 2B/3 STUDY WITH DIPRAGLURANT FOR DYSKINESIA ASSOCIATED WITH PARKINSON’S DISEASE Geneva, Switzerland, June 29, 2021 – Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering...
Sierra Oncology Announces Completion of Enrollment for MOMENTUM Phase 3 Trial—Topline data anticipated in Q1 2022 with NDA filing to follow in H2 2022— SAN MATEO, Calif., June 21, 2021 /CNW/ – Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical...
Recent Comments